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Abstract 
 
Background and Aims: Twin and family studies suggest that there is a significant 
heritable component to primary biliary cirrhosis (PBC). Selected cytotoxic T 
lymphocyte associated antigen-4 (CTLA4) gene polymorphisms have been proposed 
as “non-specific determinants of disease risk” in a variety of autoimmune diseases, 
including PBC. However, there has been considerable debate over the validity of 
these associations and the precise location of the disease promoting polymorphism. 
Methods: We have investigated six single nucleotide polymorphisms in the CTLA4 
gene in a total of 327 PBC patients and 391 healthy controls: 247 patients and 292 
controls from the United Kingdom and a further 80 patients and 99 controls from 
northern Italy. Results: The previously reported association with CTLA4 A+49G was 
not replicated in the Italian series, and there were no significant differences in the 
distribution of any of the six polymorphisms comparing; allele, genotype or haplotype 
distribution in patients versus healthy controls in the UK series. Furthermore, there 
were no significant associations with the clinical variables; histological stage, portal 
hypertension or Mayo score. However, when PBC-40 Fatigue Domain scores were 
considered a number of significant trends were noted, but none were significant after 
correction for multiple testing. Thus, fatigues score were higher in those with the 
CTLA4 -319 T allele (p<0.05, pc not significant) and in those with the CTLA4 +49 
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AA genotype (p<0.05, pc not significant). Conclusions: Contrary to previous reports 
the CTLA4 gene is not a major risk factor for PBC, nor is it major determinant of 
disease progression.  
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Introduction 
Primary biliary cirrhosis (PBC) is an autoimmune liver disease characterised 
by immune mediated damage to the biliary epithelial cells lining the small intra-
hepatic bile ducts1. Although PBC is not a Mendelian autosomal or sex-linked genetic 
disease, clustering of the disease in families2-5 and specific geographic regions6, 
together with the recent reports of a 63% concordance rate in monozygotic twins7, and 
a sibling relative risk [λs] of 10.5 for PBC5, suggest that there may be a significant 
heritable component to this disease.8-10 Despite this the role of genes in PBC 
pathogenesis remains poorly understood and though female sex and specific HLA 
alleles and haplotypes8-11 have been shown to be important determinants of disease 
risk, studies of other genes have produced mixed results.  
Over the past 5 years there has been considerable interest in the role played by 
non-MHC immuno-regulatory genes in autoimmune disease, especially the T-cell 
regulatory gene CTLA4 on chromosome 2q33. In particular, CTLA4 polymorphisms 
have been proposed as “non-specific determinants of disease risk” in a variety of 
autoimmune diseases.12 Studies of CTLA4 polymorphism in type I diabetes and 
Graves’ disease abound12-14, yet there is no general consensus regarding the overall 
role of CTLA4 polymorphism in autoimmunity nor is there a consensus regarding the 
precise location or identity of the disease causing mutations or haplotypes.  
Liver disease is no exception to this pattern. Early studies reported significant 
associations between the CTLA4 A+49G SNP and the autoimmune liver diseases; 
PBC15 and type 1 autoimmune hepatitis.16 However, with the exception of an isolated 
report of a similar association from China,17 these associations have not been widely 
replicated and recent studies have excluded the possibility of a major genetic 
association with the third “autoimmune” liver disease - primary sclerosing 
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cholangitis.18 Disease heterogeneity which often results in case ascertainment bias, 
and/or the limited extent of the investigations so far may be significant factors in this 
failure.19  
In PBC “disease heterogeneity” embraces such diverse phenotypic 
considerations as immune status, various different markers of disease progression and 
none-stage associated symptomatic manifestations of the disease. Of the latter, fatigue 
which is present in up to 50% of patients appears to have the greatest impact on 
patient quality of life (QOL). Despite its clinical importance, the pathogenesis of 
fatigue is unclear though studies have consistently shown that the severity of fatigue 
is independent of all other parameters of liver disease severity.20-25  
The alternative explanation for the lack of a consensus regarding the role of 
CTLA4 gene polymorphisms in autoimmune disease may be that we have been 
looking at the wrong region of the genome and/or overlooking significant genetic 
detail. The most recent studies in diabetes and Graves’ disease have suggested that the 
key SNP within the CTLA4 gene is not A+49G, but is instead an A/G SNP in the 6.1-
kb region 3’ of CTLA4.26 This SNP (referred to as CT60) is associated with inherited 
variation in the efficiency of the splicing and production of soluble (s) compared with 
full length (fl) isoforms of CTLA-4 mRNA. Furthermore the disease susceptibility 
allele CT60*G is associated with lower levels of sCTLA-4 mRNA production. CTLA-
4 is expressed on CD25 T cells and acts to down-regulate the immune response 
through competition with CD28 bearing T cells via CD80/CD86. It has been proposed 
that lower levels of sCTLA-4 in serum could lead to reduced efficiency of blocking of 
CD80/CD86 permitting increased or prolonged activation of CD28 T-cells.26 
The aims of the present study were three-fold. First; to attempt to replicate our 
earlier findings of an association with CTLA A+49G15 in a second population of PBC 
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patients. Second; to extend the original observations to include a more thorough 
analysis of CTLA4 haplotypes in PBC, including; the 5 SNPs required for 
identification of the most common (tagged haplotypes) identified by Johnson et al.,27 
and the more recently identified diabetes-associated CT60 SNP identified by Udea et 
al.,26. Third; to consider in the analysis the relationship between CTLA4 
polymorphism and clinical phenotype as determined by: histology score, presence or 
absence of portal hypertension, Mayo risk score and the symptom of fatigue. 
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Patients and Methods 
 A total of 327 well-characterized PBC patients and 391 “healthy” controls 
were studied. Patients and controls were recruited from two different centers as 
follows.  
Subjects: Italian Series 
80 consecutive well-characterised PBC patients with a median age of 43 years 
(range 18 – 73 years) were studied. All were of European ancestry and resident within 
the Padova area of northern Italy. Eight were male (10%) and 72 female (90%). All 
subjects had definite disease using standard criteria (all three of: a) liver histology 
diagnostic of, or compatible with, PBC, b) cholestatic liver function tests and c) 
positive serum anti-mitochondrial antibody titre ≥ 1:40 detected by 
immunofluorescence using composite tissue blocks. Subjects were excluded from the 
study if their biopsy (or any other clinical data) suggested additional, potentially 
confounding causes for liver pathology. In 76 patients liver biopsies were reviewed 
for confirmation of diagnosis to determine stage. Patients were classified as 
“advanced (late) disease” i.e. Scheuer stage III or IV and “early disease” i.e. Scheuer 
stage I or II.28 Forty-one (54%) had histologically advanced disease on their last liver 
biopsy. 
For comparison 99 Italian controls matched by geography, sex and racial 
origin were also studied. All subjects were of northern European Caucasoid origin and 
resident in and around Padova, northern Italy. All subjects and controls gave informed 
consent and the study was cleared by the local hospital ethics committee. DNA 
samples were labelled and stored by code only and analysed without prior knowledge 
of individual identities. 
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Subjects: UK Series 
The UK group comprised 247 well-characterised patients with a median age of 
64 years (range 23 – 85 years). All were of northern European ancestry and resident 
within the Newcastle area defined by postal code.6 Twenty-seven were male (11%) 
and 220 female (89%). All subjects had definite disease using the same diagnostic 
criteria as for the Italian series. Liver histology data from within 6 months of the 
collection of DNA was available in 217 patients One hundred and forty-four patients 
(66%) had histologically advanced disease (Scheuer stage III or IV) and seventy-three 
(34%) had early disease on their last liver biopsy.28 Additional data were available 
regarding:  
1) Portal hypertension in 210 patients (defined as the presence of oesophageal 
varices at endoscopy and/or ascites either clinically or radiologically).  By 
these criteria 93 patients were diagnosed as having portal hypertension 
2) Mayo risk score, available in 141 patients (median 4.15; range 2.42 – 8.27)  
3) QOL in 100 PBC patients assessed using the PBC-40 a fully validated disease-
specific QOL measure containing a fatigue-specific domain optimised for the 
assessment of fatigue in PBC patients.29 
For comparison 292 geographically and racially matched controls from north east 
England were studied. All subjects and controls gave informed consent and the study 
was cleared by the ethical committee of the Newcastle Hospitals Trust. Samples were 
labelled and stored by code only and analysed without prior knowledge of individual 
identities. 
 
Genomic DNA was extracted from 10ml of EDTA whole blood by standard 
phenol/chloroform extraction protocol.  
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Determination of CTLA4 SNPs 
For each of the SNPs tested (with the exception of CT60): 1µl of genomic 
DNA (20 - 200ng) was amplified in a 25µl reaction mixture containing 200µM each 
of dATP, dCTP, dGTP and dTTP (ABgene Surrey, UK), 1.5mM MgCl2, 10mM tris-
HCl pH8.3, 50mM KCl, 0.01%w/v gelatin, 0.5µM of each primer (Oswel, 
Southampton, UK: table 1) and 1 to 1.5U Taq Polymerase (ABgene) on a Perkin-
Elmer GeneAmp 9700 according to the following protocols: 
 
T-1722C 
A 511bp fragment of the CTLA4 promoter was amplified in a 25µl reaction 
mixture (above) according to a modification of the method of Johnson et al.27 
Conditions for amplification were as follows: 940C for 5 minutes; 35 cycles of: 940C 
for 60 seconds, 560C for 60 seconds, 720C for 60 seconds followed by a single final 
extension at 720C for 10 minutes. Following amplification, 15µl of the amplicon were 
digested for 3 hours with an excess of the restriction endonuclease BbvI (New 
England Biolabs (UK) Ltd, Herts, UK) at 370C. Digested restriction fragments were 
visualised on a 2% w/v agarose gels with appropriate commercially available size 
markers (New England Biolabs). The exchange of C for T at position -1722 creates 
the BbvI restriction site and digestion of the amplicon results in fragments of 91 and 
420bp in those with the C allele.  
A-1661G 
A 511bp fragment of the CTLA4 promoter was amplified as above with the 
same conditions for amplification. Following amplification, 15µl of the amplicon 
were digested for 3 hours with an excess of the restriction endonuclease DraI (New 
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England Biolabs) at 370C. Digested restriction fragments were visualised on a 2% w/v 
agarose gels with appropriate commercially available size markers (New England 
Biolabs). The exchange of G for A at position -1661  creates the DraI restriction site 
and digestion of the amplicon results in fragments of 70 and 441bp in those with the 
A allele.  
C-658T 
A 624bp fragment of the CTLA4 promoter was amplified as above. Conditions 
for amplification were as follows: 940C for 5 minutes, 33 cycles of: 940C for 60 
seconds, 560C for 60 seconds, 720C for 60 seconds followed by a single final 
extension at 720C for 10 minutes. Following amplification, 15µl of the amplicon were 
digested for 3 hours with an excess of the restriction endonuclease AciI (New England 
Biolabs) at 370C. Digested restriction fragments were visualised on a 2% w/v agarose 
gels with appropriate commercially available size markers (New England Biolabs). 
The exchange of T for C at position -658 creates the AciI restriction site and digestion 
of the amplicon results in fragments of 153 and 471bp in those with the C allele.  
C-319T 
A 246bp fragment of the CTLA4 promoter was amplified as above. Conditions 
for amplification were as follows: 940C for 5 minutes, 35 cycles of: 940C for 60 
seconds, 600C for 60 seconds, 720C for 60 seconds followed by a single final 
extension at 720C for 10 minutes. Following amplification, 10µl of the amplicon were 
digested for 3 hours with an excess of the restriction endonuclease MseI (New 
England Biolabs) at 370C. Digested restriction fragments were visualised on a 2% w/v 
agarose gels with appropriate commercially available size markers (New England 
Biolabs). The 246bp amplicon contains a constitutive MseI restriction site. 
Consequently upon digestion with MseI all of the amplicons were reduced in length 
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by 21bp to 225bp. However, the exchange of C for T at position -319 creates a further 
MseI restriction site and digestion of the amplicon results in fragments of 93 and 
132bp in those with the T allele.  
A+49G 
A 328bp fragment of the CTLA4 promoter was amplified in a 25µl reaction 
mixture (above) according to the method of Agarwal et al.15 Conditions for 
amplification were as follows: 940C for 5 minutes, 35 cycles of: 940C for 60 seconds, 
57.50C for 60 seconds, 720C for 60 seconds followed by a single final extension at 
720C for 10 minutes. Following amplification, 15µl of the amplicon were digested for 
3 hours with an excess of the restriction endonuclease BbvI (New England Biolabs) at 
370C. Digested restriction fragments were visualised on a 2% w/v agarose gels with 
appropriate commercially available size markers (New England Biolabs). The 
exchange of A for G at position +49 creates the BbvI restriction site and digestion of 
the amplicon results in fragments of 84 and 244bp in those with the G allele.  
CT60 
A 166bp fragment of the 3’ UTR of CTLA4 was amplified in a 23.5µl reaction 
mixture which contained 20µl of  ReddyMixTM (75mM Tris-HCl, 20mM (NH4)2SO4, 
0.01% v/v Tween 20, 0.2mM dNTPS, 1.5mM MgCl2, 0.5U Taq polymerase: 
ABGene, Surrey, UK), 1 mM of each primer and 1µl of genomic DNA (20 - 200ng).  
Amplification conditions were as follows: 950C for 4 minutes; 35 cycles of: 950C for 
60 seconds, 590C for 60 seconds, 720C for 60 seconds; followed by a single final 
extension at 720C for 5 minutes. 15µl of the PCR product were digested with 10 units 
of HpyCH4IV (New England Biolabs) at 370C and fragments visualised on 2% w/v 
agarose gels.  The exchange of A for G creates the HpyCH4IV restriction site and 
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digestion of the CT60 amplicon results in fragments of 89 and 79bp in those with the 
G allele.  
 
Data analysis and Statistics 
 For haplotype analysis we used the haplotype tagging (ht) method proposed by 
Johnson et al.,27 which was developed to “significantly reduce the genotyping effort 
when looking for genetic determinants of common disease.” One additional advantage 
of using this method for investigation of CTLA4 is that the ht-SNPs have already been 
identified.27 However, this information pre-dates the identification of the CT60 SNP 
by Udea et al.,26 Therefore haplotype data were determined in two stages. First, 
haplotypes of the 5 tagged SNPs in the CTLA4 gene (i.e. -1722, -1661, -658, -319, 
+49) were assigned manually based on the expected patterns of linkage 
disequilibrium.27 These data were compared with the published data27 and then the 
data for the CT60 SNP were added and the six SNP haplotypes determined based on 
the known patterns of linkage disequilibrium.  
 The genotype distribution in each sample set was tested for deviation from 
Hardy-Weinberg Equilibrium. 
 To tests for genetic associations with overall risk of PBC the distribution of 
genotypes and alleles and haplotypes were compared using χ2 test and/or Fisher’s 
exact probability test as appropriate with Statcalc on EpiInfo software (CDC Atlanta, 
Georgia).  
To test for genetic associations within disease phenotype the relationship 
between genotypes, alleles and haplotypes and clinical variables was tested using χ2 
test and/or Fisher’s exact probability test for the discontinuous variables and students 
T test for continuous variables. In this exercise presence or absence of portal 
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hypertension, stage I/II versus stage III/IV histology and Mayo risk scores were 
treated as discontinuous variables and the PBC-40 fatigue domain scores were treated 
as continuous variables. As there were no a priori associations within any of the four 
clinical sub-groups (histological stage, Mayo score, portal hypertension and fatigue) a 
correction factor of 4 was applied to all probability values generated in the analysis of 
phenotypes. 
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Results 
Hardy-Weinberg Equilibrium: There were no significant deviations from the 
expected genotype distribution for any of the six SNP genotypes in any of the four 
study groups tested. 
 
Comparison of CTLA4 A49G SNP allele and genotype distribution in Italian 
PBC patients versus healthy Italian controls (table 2): There was no significant 
difference in the distribution of the CTLA4 A+49G alleles or genotypes in Italian 
patients versus Italian controls. Indeed the only trend seen in the Italian group was a 
slight increase in the G allele frequency in controls compared to patients. This was 
due to a small increase in the GG genotype compared with the AG genotype in 
controls versus patients (table 2).  
 
Comparison of CTLA4 SNP allele, genotype and haplotype distributions in UK 
PBC patients versus Healthy UK controls (tables 3, 4, 5 and 6): In the UK series 
there were no significant differences in the distributions of any of the six CTLA4 SNP 
alleles or genotypes in patients compared to healthy controls. In addition there were 
no significant differences in the distribution of the six common CTLA4 htSNP 
haplotypes (table 5) (as identified by the haplotype tagging method)27 or the six-SNP 
extended haplotypes (table 6).   
Furthermore, observed patterns of linkage disequilibrium and haplotype 
frequencies for the 5 tagged SNPs, were not significantly different from published 
patterns (see footnote to table 5).27 There were slightly lower frequencies of haplotype 
1 and slightly higher frequency of haplotype 2 in controls compared to the data of 
Johnson et al.,27 These small variations can be attributed to population differences 
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between the two studies. There was also no deviation from the expected pattern of 
linkage disequilibrium between A49G and CT6026 with two of the four common 
haplotype groups co-segregating with the CT60*A SNP and four preferentially co-
segregating with the CT60*G SNP (table 6). 
 
Comparison of CTLA4 SNP allele, genotype and haplotype distributions in UK 
PBC patients by clinical subgroups: In the UK series there were no significant 
differences in the distribution of the CTLA4 alleles, genotypes or haplotypes in 
patients with early versus late stage histology; in those with and without portal 
hypertension and, in those with high or low Mayo Clinic scores (data not shown). 
However, when the PBC-40 Fatigue Domain scores were considered, significant 
differences were detected in the CTLA4-319 and the CTLA4+49 SNP distributions 
before correction for multiple testing. Thus, fatigue scores were significantly higher in 
those with the CTLA4-319 CT genotype (p=0.04) compared to those with the 
homozygote CC genotype, and possession of the CTLA4-319 T allele was associated 
with a significantly greater level of fatigue (p=0.05). Patients with CTLA4 +49 
homozygote AA genotype were also significantly more fatigued compared to those 
with the AG or GG genotypes (p<0.05). However, none of these differences were 
significant after correction for multiple testing. 
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Discussion 
The present study suggests that CTLA4 gene polymorphism does not play a 
major role in determining susceptibility to PBC. In addition, the absence of any clear 
relationship between CTLA4 gene polymorphism and the clinical indices; histological 
stage, portal hypertension and Mayo Clinic score all suggest that these SNPs, alleles, 
genotypes and haplotypes are not major determinants of disease progression in PBC. 
However, there may be a relationship between the CTLA4 gene polymorphisms and 
fatigue. 
The opening observations of the present study are contrary to previously 
published data from our centre, wherein a moderate genetic association with PBC was 
reported.15 Such contradictions are not unusual or without precedent.  Earlier studies 
in type 1 diabetes (T1D), autoimmune thyroid disease and celiac sprue all reported 
strong to moderate effects of various CTLA4 gene polymorphisms on disease risk.12 
Studies of the CTLA A+49G SNP were most successful and this SNP, which encodes 
a threonine to alanine substitution at position 17 in the first exon of CTLA4 protein, 
became the focal point for studies of CTLA4 in many different autoimmune 
diseases.12 However, more recent studies have revealed that not only is this SNP 
unlikely to be a disease causing SNP in T1D and Graves’ disease, but also the risk 
associated with the disease causing SNP is much smaller than originally suggested.26 
There are many possible and well rehearsed explanations for the lack of 
replication of the findings of case control association studies.19 In addition to the usual 
statistical considerations19, we need to consider: case ascertainment bias, genotyping 
errors and control selection. Case ascertainment bias occurs most often when the 
study population comes from a tertiary referral centre. In such cases the referred 
patients may represent a particular clinical subgroup with less easily managed or more 
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severe disease. For example, one of the most recent studies of T1D has suggested that 
the modest increase in disease risk associated with the CTLA4 CT60*G allele (OR = 
1.15),26 may be confined to patients with concurrent autoimmune thyroid disease.30 
Case ascertainment bias has been reported to effect genetic associations in PBC31, but 
this does not account for the current difference.  
Genotyping errors occur in most studies, though it is generally thought they 
have minimal impact where there is adequate quality control. In the present case 
genotyping errors are not indicated as a major contributing factor for several reasons. 
First, there was a very high degree of concordance when patients from our series were 
independently retested; second, the genotype frequencies for the patient group 
presented herein are very similar to the earlier published values;15 third, a 
retrospective review of the two studies indicates very few potential errors; fourth the 
assigned genotypes conform to the expected patterns of linkage disequilibrium.27  
Case ascertainment bias and genotyping errors are relatively easy to identify in 
genetic studies and eliminate, but it is harder to identify problems related to control 
sample selection. Despite this the control group is as important as the patient group 
and a survey of major UK published series reveals similar changes in the frequency of 
particular SNPs in control series over time.26, 32 In the case of CTLA4 A+49G there 
has been a general reduction in the reported frequency of the A allele in healthy 
controls and a compensatory increase in the G allele frequency over the past few 
years.26, 32 The major difference between the published series and the present series 
with respect to A+49G is in fact related to the differences in the healthy control 
populations used in the two studies. The first controls group were hospital based 
volunteers, whilst the second were recruited through several large local businesses 
and may be more representative of the local population. Interestingly the current 
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control data are more consistent with figures from elsewhere in the United 
Kingdom.26  
The present findings with respect to fatigue need to be confirmed in an 
independent series. As intriguing as the potential associations are they are not 
significant after correction for multiple testing. Given the questionable reliability of 
case control association studies, when they are based on small numbers19, it is perhaps 
too early to draw any conclusions from this putative association. However, there are 
also two reasons why this unexpected result should not be completely dismissed. 
First, the present study includes QOL data for 100 patients only and this fatigue 
subgroup is not of  adequate size to detect small to moderate genetic effects such as 
may be expected in complex disease.19 Thus rejecting this trend out of hand may be 
premature and based on a type II statistical error. Second, fatigue is a debilitating 
problem and though studies in animal models and patients have suggested that it is 
central in origin and related to dysfunction of the HPA axis33, 34 and/or altered 
manganese homeostasis24 there are few firm clues as to its origins. The results of the 
present study, if confirmed would indicate that CTLA4 gene polymorphisms may 
convey a significant risk of fatigue symptoms in PBC and this opens new avenues for 
future investigations offering hope to a large number (up to 50%) of PBC patients.   
Overall the present study has failed to replicate earlier claims of a genetic 
association with CTLA4 A+49G and PBC15 and it highlights, once again, the need for 
better planning when conducting case control association studies. Furthermore, a 
thorough analysis of extended haplotypes clearly demonstrates that the CTLA4 gene 
does not play a major role in either disease susceptibility per se or disease progression 
in PBC. This finding is in keeping with recent observations in primary sclerosing 
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cholangitis18 and the continuing controversy over the role of this gene in type 1 
diabetes.31 
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Table 1: PCR primer sequences: 
SNP Primers Sequences 
T-1722C Forward 5'- TCC Tgg TTA CAT TTC TCC CTg AA - 3' 
 
Reverse 5'- TCA AgC gCC AAC AAg CAA T - 3'  
 
  
A-1661G Forward 5'- Agg AAg TgC CCA TTA ggT Tg - 3' 
 
Reverse 5'- TCA AgC gCC AAC AAg CAA T- 3'  
 
  
C-658T Forward 5'- AgT CTA TCC TTT TAT ggA Cgg C- 3' 
 
Reverse 5'- TTA CgA gAA Agg AAg CCg Tg  - 3' 
 
  
C-319T Forward 5’- AAA TgA ATT ggA CTg GAT GGT - 3’ 
 
Reverse 5'- TTA CgA gAA Agg AAg CCg Tg - 3' 
 
  
A+49G Forward 5’- CCA Cgg CTT CCT TTC TCg TA - 3’ 
 
Reverse 5’- AgT CTC ACT CAC CTT TgC Ag - 3’ 
 
  
CT60 Forward 5’- CTT TgC ACC AgC CAT TAC CT - 3’ 
 Reverse 5’- gAA Agg ggA ggT gAA gAA CC - 3’ 
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Table 2: CTLA+49G SNP in Italian PBC patients and controls genotype and allele 
distribution 
  number and (percent)  
 Genotype Patients Controls P value 
     
A+49G AA 40 (55) 54 (54) ns 
 
AG 29 (40) 35 (35)  
 
GG 4 (5) 10 (10)  
 
    
 
Allele    
 
    
 
A 109 (75) 143 (72) ns 
 
G 37 (25) 55 (28)  
 
    
 
Footnote: All 80 Italian PBC patients and 99 Italian controls were studied. However a 
number of samples failed to amplify on more than one occasion and therefore the total 
number  data on 73 patients were available for analysis.   
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Table 3: Summary of SNP genotype distributions in UK patients and controls 
  number and (percent)  
SNP Genotype Patients Controls P value 
T-1722C CC 0 1 (0.3) ns 
 
CT 44 (18) 40 (14)  
 
TT 202 (82) 251 (86)  
 
    
A-1661G AA 164 (67) 206 (71) ns 
 
AG 78 (32) 81 (28)  
 
GG 4 (1.6) 5 (2)  
 
    
C-658T CC 180 (79) 239 (82) ns 
 
CT 42 (19) 50 (17)  
 
TT 5 (2) 1 (0.4)  
 
    
C-319T CC 215 (87) 252 (87) ns 
 
CT 31 (13) 36 (13)  
 
TT 0 1 (0.3)  
 
    
A+49G AA 75 (31) 106 (36) ns 
 
AG 130 (53) 142 (49)  
 
GG 38 (16)  43 (15)  
 
    
CT60 AA 32 (16) 57 (21) ns 
 AG 104 (53) 137 (50)  
 GG 59 (30) 82 (30)  
 
Footnote: All 247 PBC patients and 292 controls were tested for all six SNPs. 
However, a number of the samples failed to amplify on more than one occasion and 
therefore the total of data points varies for each SNP tested.   
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Table 4: Summary of SNP allele distributions in UK patients and controls 
  number and (percent)  
SNP Genotype Patients Controls P value 
T-1722C C 44 (9) 42 (7) ns 
 
T 448 (91) 542 (93)  
 
    
A-1661G A 406 (83) 493 (84) ns 
 
G 86 (17) 91 (16)  
 
    
C-658T C 402 (89) 528 (91) ns 
 
T 52 (12) 52 (9)  
 
    
C-319T C 461 (94) 540 (93) ns 
 
T 31 (6) 38 (7)  
 
    
A+49G A 280 (58) 354 (61) ns 
 
G 206 (42) 230 (39)  
 
    
CT60 A 168 (43) 251 (45) ns 
 G 222 (57) 301 (55)  
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Table 5 htSNP haplotype distribution for common (>5%) CTLA4 haplotypes 
Haplotype SNP Position Number and Percent 
 -1722 -1661 -658 -319 +49 Patients Controls 
1 T A C C A 134 (28) 211 (36) 
2 T A C C G 153 (32) 186 (32) 
3 T G C T A 23 (5) 39 (7) 
4 T A T C A 45 (9) 51 (9) 
5 C A C C G 42 (9) 42 (7) 
6 T G C C A 57 (12) 53 (9) 
Other      32 (7) 0 
 
Footnote: Haplotypes 1 – 6 above correspond to the 11 haplotypes presented by 
Johnson et al., Though the haplotype tagging method is designed to recognise 
haplotypes with a frequency of 5% or greater Johnson et al.,38 used additional SNPs 
within CTLA4 to identify some haplotypes that are less common. Thus in our scheme 
haplotype 1: corresponds to common haplotype A, G less common haplotypes G and J  
of Johnson et al.38 (with a combined expected frequency of 39.3%).  Haplotype 2 
(above): corresponds to the common haplotype B & I (24.4%); haplotype 3: 
corresponds to the haplotype C only (8.6%); haplotype 4: corresponds to both 
haplotypes D and K (9.7%); haplotype 5: corresponds to the haplotype E (5.8%) and 
haplotype 6 corresponds to haplotypes F and H (7.5%).    
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Table 6: Six-SNP haplotype distribution for common (>5%) haplotypes.  
Haplotype SNP position Number and Percent 
 -1722 -1661 -658 -319 +49 CT60 Patients Controls 
1 T A C C A A 113 (31) 209 (36) 
2 T A C C G G 115 (32) 183 (32) 
3 T G C T A G 18 (5) 40 (7) 
4 T A T C A A 30 (8) 50 (9) 
5 C A C C G G 32 (9) 41 (7) 
6 T G C C A G 41 (11) 51 (9) 
 
Footnote: Published values for this six-SNP haplotype are not available for 
comparison.  
